Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, announced today that data from a completed Phase 3 clinical trial of SUSTOL™ (granisetron), the Company’s lead product candidate for the prevention of acute-onset chemotherapy-induced nausea and vomiting (CINV), will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, June 1, 2014 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
